Bangkok Dusit Medical Services : Minutes of Annual General Meeting of Shareholders for the Year 2024

Directors attending the meeting via video conference:

Directors who did not attend the meeting:

There were 15 directors of the Company. 14 directors attended the meeting, representing 93.33 percent of the total number of directors.

Attendees:

Page 2 of 22

Legal advisor from Weerawong, Chinnavat & Partners Ltd.:

Preliminary proceedings:

Miss Kessara Wongsekate, the Company Secretary, informed the Meeting that there were 2,720 shareholders attending the Meeting in person and by proxy, representing 10,814,817,250 ordinary shares, equivalent to 68.05% of the total number of paid-up and issued shares of the Company. A quorum was thus constituted in accordance with Article 33 of the Articles of Association of the Company, which provides that, at a shareholders' meeting, the presence of no fewer than 25 shareholders and/or proxies appointed by shareholders that hold shares amounting to no less than one- third of the total number of sold shares in aggregate, is required to constitute a quorum.

Professor Emeritus Santasiri Sornmani, M.D., the Chairman of the Board of Directors, who presided as the Chairman of the Meeting (the "Chairman"), declared the 2024 Annual General Meeting of Shareholders (the "Meeting") duly convened and introduced the directors, executives of the Company, and external attendees, who were representatives of the auditor and the legal advisor of the Company. The Chairman then delegated Miss Kessara Wongsekate, the Company Secretary, to inform the Meeting of the procedures for casting votes, as follows:

Miss Kessara Wongsekate, the Company Secretary, explained that, to ensure that the Meeting complied with the principles of good corporate governance, for the voting part of the Meeting, the Company would explain the procedures for voting and the counting of votes, as set out below.

1. The Shareholders can log-in to the E-voting system using the same username and password which are used for registration.
2. Voting in this Meeting shall be counted as one share is equivalent to one vote.
3. The Meeting will consider matters in the order specified in the notice of the Meeting. Each agenda item will be presented, providing an opportunity for the shareholders to ask questions before voting. The results will be announced during the Meeting after the vote counting for each agenda item is completed.
4. During the voting process, the shareholders shall select the agenda item which wish to vote and then press the "Vote" button. The system will display three voting options: "Approve",
   "Disapprove", and "Abstain". In vote counting, the Company will deduct the votes cast against or in abstention of an agenda item from the total number of votes, and the remaining number will be treated as the votes of approval.

Page 3 of 22

For those holding proxies from multiple shareholders, the system will display a list of all shareholders who have provided their proxies. The proxies can vote collectively on behalf of all shareholders or vote separately for each shareholder.

1. To cancel a vote, the shareholder shall press the "Cancel Voting" button. If a shareholder has not voted within the specified time, including those who cancel their votes and fail to submit a new vote, the Company will assume that the shareholder agree with the respective agenda item. In this regard, votes can be modified until the Company announces the closure of voting for each agenda item. The Company provides a two-minute voting in each agenda item, except for voting in the director election agenda item, which is provided a four-minute voting. Once voting for each agenda item is closed, the Company will announce the results to the Meeting.
2. In the event that the shareholders leave the Meeting before voting on any agenda item is closed, their votes will not be counted as a quorum for the said agenda item, nor will be counted for the remaining agenda items. However, leaving the quorum for any agenda item will not prevent the shareholders or proxies from returning to the Meeting and voting on subsequent agenda items.
3. In the event that there are numerous questions related to a particular agenda item submitted to the system with similar concerns, the Company may consider selecting or consolidating questions to keep the Meeting concise. If there are numerous questions, the Company will gather them and address them in the subsequent shareholder meeting report.
4. In the event that the shareholders encounter difficulties in accessing the Meeting or voting system, please study and follow the instructions provided with the notice of the Meeting or select the "Help" menu in the system. The Shareholders can contact Inventech call center staff at 02-931-9138 or via the LINE Official account @inventechconnect.
5. If a system failure occurs during the shareholder's meeting, the shareholders will receive an email notification containing a backup link to return to the meeting via the backup system.

The Chairman then informed the Meeting that, in preparation for this 2024 Annual General Meeting of Shareholders, from 1 December 2023 to 14 January 2024, the Company gave the shareholders the opportunity to propose matters that would be beneficial and appropriate as agenda items in advance of this Meeting, as well as to nominate a person who is knowledgeable, competent, and qualified for appointment as a director. The guidelines for proposing such additional matters were posted on the Company's website. By the end of the given period, no shareholder had proposed any matter in advance for the Board of Directors to consider and add to the list of agenda items for this Meeting, and there was no nomination of other qualified persons for appointment as directors. Thereafter, the Chairman proceeded with the Meeting in accordance with the following agenda items:

Page 4 of 22

Agenda Item 1: To acknowledge the Company's 2023 performance

The Chairman assigned Miss Poramaporn Prasarttong-Osoth, M.D., the President, to inform the Meeting of the Company's performance during the year 2023.

Miss Poramaporn Prasarttong-Osoth, M.D., President, presented to the Meeting an overview of the performance of the Company during the year 2023. The important details are summarized as follows:

Overview of the Company

• As of 31 December 2023, the Company ("BDMS") had 58 hospitals in its network, operating under various brands, which consisted of Bangkok Hospital, Samitivej Hospital, Phyathai Hospital, Paolo Hospital, BNH Hospital, and Royal Hospital, which were hospitals in Cambodia, with a total of approximately 8,600 hospital beds. From the total number of 58 hospitals, 14 of which are determined as hospitals with the Center of Excellence.
• At the end of 2023, the BDMS group had more than 12,000 physicians, 10,000 nurses and 26,000 employees.
• The Company has businesses that supports hospitals and health services, namely, National Healthcare Systems Co., Ltd., A.N.B. Laboratories Co., Ltd., The Medicpharma Co., Ltd. which is pharmaceutical factory, Save Drug pharmacy, BDMS Wellness Clinic and BDMS Wellness Resort.

Operational Strategy

BDMS has planned operational strategies for year 2024 as follows:

Expanding Health Services

• From the total number of 58 hospitals in its network, the Company has the hospitals with secondary care, tertiary care, and super tertiary care which are the Center of Excellence. The Company aims to expand its health services to be comprehensive, not solely focusing on curative care but also extending the scope of services into preventive care, which covers early disease detection, prevention, and health promotion. These activities will be provided in hospitals and wellness clinics. In addition, after receiving medical treatment, patients may still require care before returning to their normal lives. Therefore, the Company also provides care and rehabilitation services called Transitional Care & Rehabilitative.

The Center of Excellence

• The Center of Excellence consists of 14 hospitals across Thailand and 1 hospital in Cambodia. There are 5 groups of disease that BDMS emphasizes on the Center of Excellence, namely heart

Page 5 of 22

diseases, cancer, brain diseases, bone diseases, and trauma. In 2023, the Company generated 60% of its total revenue from the Center of Excellence. The EBITDA margin from the Center of Excellence was approximately 26% of revenue, which accounted for 63% of the Company's total EBITDA

Striving for sustainability

• Medical Innovation: The Company strives to sustainability through relying on medical innovation medical to promote sustainable growth of its business, namely:
• • BeDee: An application provides healthcare services, focusing on convenience, and accessible anytime and anywhere, e.g. providing consultations on medical treatment by physicians and making appointments with physicians (Teleconsultation), providing consultation with the pharmacist (Telepharmacy), a store that sells health-related goods and products (Health Mall) and health examination appointment services and information on health examination results for each service recipient (Health Passport).
  • Smart Hospital: Implementing medical innovation to develop hospital services, e.g. accessing hospital services in the form of an application, namely, "My B+" by Bangkok Hospital Group, "Well" by Samitivej Hospital Group, and "HealthUp" by Phyathai Hospital and Paolo Hospital Group. These applications will help support healthcare services for service recipients covered by health insurance more conveniently. Previously, documents were required for insurance claims, but this will be changed to claim through the electronic systems. In the health service sector, there will be Teleconsultation services, allowing consultations with physicians through the electronic system, providing blood test services at residences, including delivery of medicines to residences. In addition, patients receiving services at the hospital can also make payments through the electronic systems by E-billing or E-payment systems using various forms such as QR codes or credit cards.
  • Innovation: The Company has invested in innovative development with both domestic and foreign startup companies to enhance efficiency of BDMS's healthcare services and lead to sustainable healthcare. In addition, the Company also cooperates with various institutions, namely, domestic and foreign universities, along with partners who assist BDMS in developing healthcare in other areas. As a result of these investments and cooperations, the Company will have more new products or services.
• Third Party Player Base Expanding: the BDMS group focuses on customers in the health insurance group. In 2018, the Company had customers in the health insurance group in the number of 29 percent of total customers. In 2023, the Company's customers in the health insurance group have grown to 36 percent of total customers. In addition, the Company also has a group of customers who are insured persons or social security. In 2024, it is expected that the number of

Page 6 of 22

delivered value to service recipients, communities, and society through the implementation of a total of 657 innovation development projects. In addition, the Company has raised sustainability awareness among all its key direct suppliers, all of which have been evaluated for ESG risk. For the year 2024, the company has plans to elevate enterprise-level IT management for sustainability, integrate enterprise risk management across the entire supply chain, and drive a culture of innovation to promote sustainable business efficiency. To become a smart hospital, the Company cooperated with leading startup companies of the country. In addition, the Company is committed to environmentally friendly procurement (Green Procurement) and promotes the procurement of products in the domestic products.

Awards to Our Great Pride

In the past year, the Company has received the following awards:

• One of the World's Best Hospitals 2023 - Thailand from Newsweek & Statista magazine.
• Thailand's Most Admired Company 2022-2023 from BrandAge.
• Best Innovative Company Awards and Best Investor Relations Awards from SET Award 2023 by the Stock Exchange of Thailand
• Awards from the IAA Awards for Listed Companies 2022 - 2023 by the Investment Analyst Association (IAA) as follows:
• • IAA Awards for Listed Companies- Outstanding CEO
  • lAA Awards for Listed Companies - Best CFO
  • lAA Awards for Listed Companies - Best Investor Relations
• The Most Honored Company Award: Healthcare, Pharma & Biotech Sector in Asia (Ex - Japan) from Institutional Investor Magazine.
• The Best Healthcare Company in Thailand Award from the 2023 Finance Asia's Best
  Companies in Asia Poll by Finance Asia Magazine.
• Awards from "Asia's Outstanding Companies Poll 2023" by Asiamoney as follows:
• • Overall Most Outstanding Company in Thailand
  • Best for ESG in Thailand
  • Most Outstanding Company in Thailand - Healthcare Sector
• Awards from "Asia's Greatest Brands and Leaders 2023" by Asia One Magazine and URS
  Media Consulting International for the medical business group as follows:
• • Asia's Greatest Brands 2023
  • Asia's Greatest CFO 2023

Page 9 of 22

The Chairman then gave the shareholders an opportunity to ask questions or express opinions in relation to this agenda item. No shareholders asked questions or expressed opinion; the Chairman then requested the Meeting to acknowledge the Company's 2023 performance.

Resolution:The Meeting acknowledged the Company's 2023 performance.

Agenda Item 2: To consider approving the Company and its subsidiaries' audited

consolidated financial statements for 2023

The Chairman proposed that the Meeting consider and approve the consolidated financial statements for the year 2023, as detailed in the Financial Statements and the Auditor's Report in the Annual Registration Statements (Form 56-1 One Report), as delivered to the shareholders in the form of QR Code together with the notice of the Meeting, and asked Mr. Chavalit Sethameteekul, the Chairman of the Audit Committee, to explain the information in support of the Meeting's consideration.

Mr. Chavalit Sethameteekul, the Chairman of the Audit Committee, informed the Meeting that the Audit Committee had considered the information in the auditor's report and the consolidated financial statements for the year ended 31 December 2023, which had been audited by Mr. Wichart Lokatekrawee, the Company's certified public accountant from EY Office Limited, and was of the view that the financial statements had been prepared in accordance with accounting standards and reflected accurate information by disclosing sufficient material facts. The auditor was also of the view that the financial statements accurately represented the Company's financial position, operating results, and cash flow, in accordance with financial reporting standards. Also, the Audit Committee was of the view that the related party transactions that occurred in the year 2023 and that appear in the Annual Registration Statements (Form 56-1 One Report) were reasonable and had been made on an arm's length basis. A summary of the income statement and statement of financial position as at the end of the year 2023 for consideration by the meeting is as follows:

Summary of the 2023 Income Statement

Page 10 of 22